



Wilhelm Stahl, Ph.D.

SUMMARY

Seasoned pharmaceutical industry thought leader with vision to identify creative solutions for pharmaceutical companies which brings new products to patients, while providing a significant financial return to clients. Dr. Stahl's broad based executive experiences in leading manufacturing, research, and medicinal chemistry organizations provides a unique and valuable perspective for Rondaxe customers .

PROFESSIONAL EXPERIENCE

Managing Member, Rondaxe: 2009-Present

- Minority owner of Rondaxe, and President of Rondaxe Deutschland, OHG
- Responsible for Sales & Marketing activities for all Rondaxe entities
- Strategic consultant to Rondaxe customers

Head of Business Lines: Pharma, Fine Chemicals, Lanxess, since April 2006 Saltigo (independent legal entity): 2005-2008

- Custom manufacturing of active pharmaceutical ingredients and intermediates
- Full business responsibility for Saltigo's pharma business including process development
- Marketing & sales and manufacturing strategy
- Overall responsibility for science and technology for Saltigo

Head of R&D/Marketing Pharma: 2002-2005; Head of Fine Chemicals, Bayer Chemicals/Lanxess: 2004-2005

- R&D: Process development, route scouting, development of new methodologies, global scientific collaboration network, homogenous catalysis
- Marketing: profit and loss responsibility, managing marketing and sales organization, provider of chemical and technical services

Head of Life Sciences Research – Central Research, Bayer AG: 2001 – 2002

Central Research, Bayer AG

- Research: combinatorial chemistry, drug discovery chemistry, genomics, proteomics, pharmacogenomics, computational chemistry, bioinformatics as a technology oriented service provider for Bayer's life science divisions Pharma, Crop Protection, Diagnostics, Animal Health

Head of Medicinal Chemistry V, Chemical Research - Pharma Division, Bayer AG: 1999-2000

- Research: medicinal chemistry, combinatorial chemistry, disorders of the central nervous system: Alzheimer, neurology, pain

Head of Screening and Acting Head of Natural Resources - Natural Products, Aventis Germany GmbH: 1998 - 1999

- Microbiology, sample preparation and logistics, high throughput screening

Head of Global Screening, HMR Germany GmbH: 1997 – 1998

- Historical compound libraries, high throughput screening technologies, natural products

Acting Head of High Throughput Screening: 1995; Head of Natural Products Team, HMR Germany GmbH: 1996

- Natural products, set up high throughput screening facility



Wilhelm Stahl, Ph.D.

Senior Scientist, Hoechst AG – Pharmaceutical Division, Frankfurt Germany: 1995 - 1995

- General Parma Research, Lead Generation Group

Senior Scientist, Hoechst AG – Pharmaceutical Division, Frankfurt Germany: 1993 - 1995

- General Parma Research, Peptide Group

Senior Scientist, Hoechst AG, Frankfurt Germany: 1991 - 1993

- Central Research Frankfurt

Assistant at the “Institut für Anorganische Chemie” and the “Institut für Organische Chemie und Biochemie” at Bonn University: 1987-1989

EDUCATION

August 1979 - February 1990
Rheinische-Friedrich-Wilhelms-Universität Bonn)

Diploma thesis: December 1985 - November 1986
Supervisor: Prof. Dr. W. Steglich
“Institut für Organische Chemie und Biochemie, Universität Bonn”

Heinrich-Hörlein-Award, 1986

Ph.D. thesis: December 1986 - February 1990
Supervisor: Prof. Dr. W. Steglich

“Institut für Organische Chemie und Biochemie, Universität Bonn”

POST-DOCTORAL EDUCATION

March 1990 - July 1991
Research Institute of Scripps Clinic
Department of Chemistry
La Jolla, CA, USA
Supervisor: Prof. Dr. K. C. Nicolaou,

Feodor-Lynen-Fellowship
Alexander von Humboldt-Stiftung



Wilhelm Stahl, Ph.D.

PUBLICATIONS

K. C. Nicolaou, R. D. Groneberg, T. Miyazaki, N. A. Styliamides, T. J. Schulze, W. Stahl, Total synthesis of the oligosaccharide fragment of calicheamicin \square_1^1 , *J. Am. Chem. Soc.* **1991**, *112*, 8193.

K. C. Nicolaou, E. P. Schreiner, W. Stahl, Synthetic strategy for the coupling of the calicheamicin oligosaccharide with aglycons: synthesis of dynemicin A-calicheamicin hybrid structures, *Angew. Chem.* **1991**, *103*, 566; *Angew. Chem. Int. Ed. Engl.* **1991**, *30*, 585.

R. D. Groneberg, T. Miyazaki, N. A. Stylianides, T. J. Schulze, W. Stahl, E. P. Schreiner, T. Suzuki, Y. Iwabuchi, A. L. Smith, K. C. Nicolaou, Total synthesis of calicheamicin \square_1^1 . 1. synthesis of the oligosaccharide fragment, *J. Am. Chem. Soc.* **1993**, *115*, 7593.

W. Stahl, U. Sprengard, G. Kretzschmar, H. Kunz, Synthesis of deoxy sialyl lewis^x analogues, potential selectin antagonists, *Angew. Chem.* **1994**, *106*, 2186.

W. Stahl, L. Kuhlmann, M. Wiesner, A. Walch, ^{99m}Tc labeling of antibodies using methylphosphonylated, bifunctional cyclams as chelators, *Bioorg. & Med. Chem. Lett.* **1994**, *21*, 2597.

A. Peyman, W. Stahl, K. Wagner, D. Ruppert, K.-H. Budt, Non-peptide-based inhibitors of human immunodeficiency virus-1 protease, *Bioorg. & Med. Chem. Lett.* **1994**, *21*, 2601.

W. Stahl, U. Sprengard, G. Kretzschmar, D. W. Schmidt, H. Kunz, Synthesis of sulfated Le^x-Trisaccharides, *J. Prakt. Chem.* **1994**, *337*, 441.

W. Stahl, G. Breipohl, L. Kuhlmann, A. Steinsträßer, H. J. Gerhards, B. A. Schölkens, Technetium-99m-labeled HOE 140: a potential bradykinin b₂ receptor imaging agent, *J. Med. Chem.* **1995**, *38*, 2799.

G. Kretzschmar, W. Stahl, Large scale synthesis of linker-modified sialyl lewis^x, lewis^x and N-acetyllactosamine, *Tetrahedron* **1998**, *54*, 6341.

F. Spaaij, J. Wink, W. Stahl, J. P. Van der Walt, G. Weber-Spaaij, *Antonie van Leeuwenhoek* **1998**, *73*, 143.

W. Stahl, What is the future of High Troughput Screening? *J. Biomol. Screen.* **1999**, *4*, 117.



Wilhelm Stahl, Ph.D.

CONTRIBUTIONS TO SCIENTIFIC SYMPOSIA

Posters

W. Stahl, A. Walch, M. Magerstädt, L. Kuhlmann, J. H. Hachmann, A. Steinsträsser, "Symposium on Synthetic Chemistry", Frankfurt, 06.-07.02.1992.

U. Sprengard, G. Kretzschmar, E. Bartnik, C. Hüls, W. Stahl, H. Kunz, European Carbohydrate Symposium, Sevilla 1995.

U. Sprengard, G. Kretzschmar, H. Kunz, E. Bartnik, C. Hüls, W. Schmidt, A. Toepfer, W. Stahl, D. Seiffge, Cell Adhesion and Inflammation, San Diego, 29-30.04.1996.

W. Aretz, G. Becker, E. Ehlers, C. Gianni, S. Grabley, P. Hammann, D. Isert, H. Kluge, H. Kogler, R. Latrell, M. Limbert, A. Markus, J. Meiwes, G. Rieß, K. Sauber, G. Seibert, W. Stahl, D. Tripier, L. Vertesy, M. Vogel, J. Wink, T. Wollmann, D. Wullbrandt, Aktuelle Entwicklungen in der Naturstoffforschung, Irsee, 21-23.02.1996.

M. Türkay, J. Wink, I. Winkler, P. Hammann, W. Stahl, Aktionstage marine Naturstoffforschung, Leipzig, 16.09.1997.

PRESENTATIONS/LECTURES

"Neue Diagnostika auf Basis von Azamakrozyklen", 66. Schultheis-Kolloquium, 03.11.1993.

"High Throughput Screening – Erfahrungen und Trends", 471. DECHEMA-Kolloquium, Frankfurt, 09.10.1997.

"Predicting the Future of High Throughput Screening", Vision in Business Ltd. - Overcoming Bottlenecks in High Throughput Screening, Brüssel, 28-29.01.1998.

"High Throughput Screening in Industrial Drug Discovery", SFB 369 Symposium: Secondary Metabolites: identification, function, regulation and evolution, München, 21-23.05.1998.

"The real versus the perceived value of miniaturization", IBC Conference, Microtechnologies & Miniaturization, Frankfurt, 02-03.09.1998.

“Vom Target zur Leitstruktur”, HMR-Vortragsreihe Pharmaforschung – Auf der Suche nach neuen Medikamenten, Frankfurt, Universitätsklinikum 19.01.1999.

“Leitstrukturgenerierung – Naturstoffe in Konkurrenz zu CombiChem und UHTS”, Bio- und Genprospektion: Beitrag zu Erhalt biologischer Vielfalt oder Auslaufmodell, Internationales Wissenschaftszentrum Heidelberg, 11-12.03.1999.

“Eine nicht-technische Einführung in die Entwicklung neuer Arzneimittel und die hierbei verwendeten Techniken” Vision im Business Ltd., Köln, 10.09.1999.